Full Press Release Details
IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 GSK959 , a Phase 1 Werner Helicase Inhibitor.
IDYA
IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 GSK959 , a Phase 1 Werner Helicase Inhibitor
Key Takeaway: IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 GSK959 , a Phase 1 Werner Helicase Inhibitor
Price reaction · baseline $18.01 (2025-03-25 close) · hit after-hours · 3 other IDYA headline(s) in the window, move may be shared
day 0 close · peak
-3.2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma